Why TIGLUTIK (riluzole) now?
For more than 20 years, physicians have relied on riluzole as a foundational therapy for their patients diagnosed and living with amyotrophic lateral sclerosis (ALS). Today, you and your patients have a choice. TIGLUTIK is the first and only oral suspension alternative to riluzole tablets specifically designed for people living with ALS who have or may develop dysphagia.1-3
Unpredictable onset of dysphagia
More than 80% of patients develop dysphagia at some point, and despite being present in about one-third of patients at disease onset, it often goes unrecognized.3
Why wait for dysphagia—when it can strike at any time?
There are hazards around dysphagia and swallowing crushed tablets4:
- Patients tend to adapt to slowly deteriorating swallowing function by changing or modifying their foods, drinks, and medicine4
- Dosage errors may result from incomplete delivery of medicine3
- Using alternative methods to administer oral medications may change how the drug is absorbed by the body, potentially affecting its safety and efficacy3
Prescribe TIGLUTIK at diagnosis
- U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Rilutek (riluzole) NDA 20599 S-013 approval package. November 16, 2009.
- TIGLUTIK (riluzole) [package insert]. Berwyn, PA: ITF Pharma; September 2018.
- Keating GM. Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Ther Perspect. 2016;32(7):282-286.
- Onesti E, Schettino I, Gori MC, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol. 2017;8:94. doi:10.3389/fneur2017.00094.
- Rilutek (riluzole) [package insert]. Cary, NC: Covis Pharmaceuticals, Inc.; April 2016.
- Data on file. ITF Pharma. Berwyn, PA. September 2018.
- Barnett N, Parmar P. How to tailor medication formulations for patients with dysphagia. Pharm J. 2016;297(7892). doi: 10.1211/PJ.2016.20201498.